認知症エンパワーメントと行動のためのイノベーション:未サービスコミュニティのためのRCT
Karen I Fredriksen-Goldsen1, Linda Teri2, Hyun-Jun Kim1
1Goldsen Institute, School of Social Work, University of Washington, Washington, DC, USA.
Journal of the American Geriatrics Society
|December 12, 2025
まとめ
認知症エンパワーメントと行動のためのイノベーション(IDEA)介入は、認知症を持つ性的および性別マイノリティの成人における身体活動と生活の質を改善するために持続的な有効性を示しました。文化的に調整された認知症ケアは、健康格差に対処するために有望です。
科学分野:
- 老年学
- 公衆衛生
- 健康格差
背景:
- 認知症ケア介入は、未サービス集団が直面する格差を見落としがちです。
- 性的および性別マイノリティ(SGM)の認知症成人は、特有の課題に直面しています。
- IDEA介入は、これらのギャップに対処するために開発されました。
研究 の 目的:
- 認知症を持つSGM成人とそのケアパートナーを対象に、標準介入(s-RDAD)と比較して、文化的に調整されたIDEA介入の有効性を比較すること。
- 身体活動、生活の質、身体機能、およびリソースリテラシーに対する両方の介入の影響を評価すること。
主な方法:
- 161組(認知症患者/ケアパートナー)を含む2群、単盲検、ランダム化比較試験(RCT)。
- IDEAとs-RDADを比較する、ずらされた複数ベースラインデザイン。
- 治療後、および30週と56週のフォローアップで評価されたアウトカム。
主要な成果:
- IDEAケアパートナーは、30週で有意に高い地域リソースリテラシーを示しました。
- 両方の介入は、治療後の認知症患者の身体活動と生活の質を改善しました。
- IDEAは、s-RDADとは異なり、30週で身体活動と生活の質の持続的な改善を示しました。
結論:
- 文化的に調整されたIDEA介入は有効であり、持続的な利益を示しています。
- 認知症介入の文化的調整は、健康格差を減らすために有望です。
- IDEAをより広範なコミュニティ設定に展開するには、さらなる研究が必要です。
さらに関連する動画
07:40Validation of a Psychosocial Intervention on Body Image in Older People: An Experimental Design
Published on: May 31, 2021
3.8K
08:53Randomized, Triple-Blind, and Parallel-Controlled Trial of Transcranial Direct Current Stimulation for Cognitive Rehabilitation after Stroke
Published on: June 6, 2025
1.5K
関連する概念動画
Community Based Intervention
258
Community-based interventions in mental health represent a paradigm shift from institution-centered care to treatments embedded within the fabric of local communities. By prioritizing inclusion and leveraging existing societal structures, this approach fosters a supportive environment conducive to addressing mental health challenges while promoting individual dignity and agency.
Foundations of Community Mental Health Programs
Central to the success of community-based interventions is the...
Foundations of Community Mental Health Programs
Central to the success of community-based interventions is the...
258
Alzheimer's Disease: Treatment
752
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
752
Dementia
486
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
486
Intellectual Disability
595
Intellectual disability (ID) is a neurodevelopmental condition characterized by deficits in intellectual and adaptive functioning that manifest during the developmental period. This condition encompasses challenges in reasoning, memory, problem-solving, and learning, accompanied by impairments in everyday life skills, such as communication, self-care, and social interactions. Intellectual disability affects approximately 1% of the population in the United States, impacting an estimated 5...
595
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Parkinson's Disease: Treatment
940
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
940
